ISSN : 0970 - 020X, ONLINE ISSN : 2231-5039
     FacebookTwitterLinkedinMendeley

Synthesis, Characterization and Single Crystal Studies of 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one

Nitinkumar S. Shetty1, Nadaf Y. F.2, Dinesh Bilehal3, Shyamkumar V.and Santosh L. Gaonkar1,*

1Department of Chemistry, Manipal Institute of Technology, Manipal University, Manipal-576104, India.

2Department of Physics and Research Center, Maharani Science College for Womens, Bangalore - 560 001. India.

3Department of chemistry, Reva Institute of Technology and Management, Bangalore-560064, India.

4Department of Biotechnology, Karnataka University, Dharwad-580003, India.

Corresponding Author E-mail: gaonkarslg@rediffmail.com

DOI : http://dx.doi.org/10.13005/ojc/320544

Article Publishing History
Article Received on :
Article Accepted on :
Article Metrics
ABSTRACT:

The paper describes industrially scalable synthesis and single crystal studies of 3-cyclopropyl-3,4-dihydroquinazolin-2(1H)-one4, a versatile intermediate in the synthesis of number of biologically active compounds. The target compound has been characterized by LC-MS, 1H NMR and IR. The crystal structure analysis shows that the title compound crystallizes in monoclinic classunder the space groupP 1 21/n 1with cell parameters, a = 10.273(2) Å, b = 8.3227(19) Å, c = 11.623(3) Å, β = 104.980(3)°, V = 960.0(4) Å3and Z=4.

KEYWORDS:

N,N'-carbonyldiimidazole; 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one

Download this article as: 

Copy the following to cite this article:

Shetty N. S, Nadaf Y. F, Bilehal D, Shyamkumar V, Gaonkar S. L. Synthesis, Characterization and Single CrystalStudies of 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one. Orient J Chem 2016;32(5).


Copy the following to cite this URL:

Shetty N. S, Nadaf Y. F, Bilehal D, Shyamkumar V, Gaonkar S. L. Synthesis, Characterization and Single CrystalStudies of 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one. Orient J Chem 2016;32(5). Available from: http://www.orientjchem.org/?p=21446


Introduction

Quinazoline derivatives are known for their anticonvulsant [1], antiinflammatory [2], and insecticidal [3] activities. There are many marketed drugs like Balaglitazone, Nolatrexed, and Verubulin containing quinazoline moiety in them [4, 5]. Many more are under clinical trial [6]. Similarly, several patents revealing applications of cyclopropylamine derivatives have whipped a curiosity among researchers.  Combination of quinazolone and cyclopropane can form an interesting moiety.  N,N’-carbonyldiimidazole (CDI) is observed to work in stereoselective acylation and also as a  coupling agent [7]. The reagent is easily handled and the imidazole byproduct formed is harmless. This imidazole is easily removed due to its solubility in a number of solvents including water, alcohol, chloroform and ether. In the case of CDI, no oxidation is detected and no decomposition of THF occurs. Quinazolin-2(1H)-one is prepared by the cyclization of an aniline derivative carrying cyclopropane moiety. CDI not just acts as a cyclizing agent but also inserts acyl group into the structure. In continuation to our work on the development of new reagents and bioactive molecules [8-13], we report herein the synthesis and crystal structure of the fused heterocycle 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one.

Materials and Methods

Chemistry

The melting points are determined on Thomas Hoover apparatus and are uncorrected. IR (KBr) spectra are recorded on Shimadzu 8300 Fourier transform infrared spectrometer. 1H NMR spectra are recorded on Bruker AM 400 MHz spectrometer using CDCl3 as solvent and TMS as an internal standard (Chemical shift in ppm). Mass spectral (MS) analysis is carried out on Agilent 6520 ESIQTOFMS with ionization source ESIQTOF and acetonitrile as solvent (110 volts). Elemental analyses are obtained on a Vario-EL instrument. Thin layer chromatography (TLC) is conducted on 0.25 mm silica gel plates (60F254, Merck). Visualization is made with ultraviolet light.

Table 1: Experimental X-ray crystallography data collection and structure refinement of 4

Chemical formula C11H12N2O
Formula weight 188.23
Temperature 296(2) K
Wavelength 0.71073 Å
Crystal system monoclinic
Space group P 1 21/n 1
Unit cell dimensions a = 10.273(2) Å α = 90°
b = 8.3227(19) Å β = 104.980(3)°
c = 11.623(3) Å γ = 90°
Volume 960.0(4) Å3
Z 4
Density (calculated) 1.288 Mg/cm3
Absorption coefficient 0.085 mm-1
F(000) 392
Theta range for data collection 2.36 to 25.17°
Index ranges -12<=h<=12, -9<=k<=9, -11<=l<=13
Reflections collected 6541
Coverage of independent reflections 99.8%
Absorption correction multi-scan
Structure solution technique direct methods
Structure solution program SHELXS-97 (Sheldrick, 2008)
Refinement method Full-matrix least-squares on F2
Refinement program SHELXL-97 (Sheldrick, 2008)
Function minimized Σ w(Fo2 – Fc2)2
Data / restraints / parameters 1715 / 0 / 127
Goodness-of-fit on F2 1.486
Δ/σmax 0.081
Final R indices 1359 data; I>2σ(I) R1 = 0.0650, wR2 = 0.1920
all data R1 = 0.0639, wR2 = 0.1328
Weighting scheme w=1/[σ2(Fo2)+(0.0835P)2+0.2218P
where P=(Fo2+2Fc2)/3
Largest diff. peak and hole 0.557 and -0.493 eÅ-3
R.M.S. deviation from mean 0.078 eÅ-3

1-cyclopropyl-N-(2-nitrobenzyl)methanamine (2):A solution of 2-nitrobenzylbromide 1 (5 g, 0.023 mol) in toluene (15 mL) is added dropwise to a solution of cyclopropylamine (13.21 mL, 0.23 mol) in toluene (30 mL) at 25-30 °C for 60 minutes. The reaction mass is stirred at room temperature for 45 minutes. Completion of reaction is marked by TLC analysis with hexane: ethyl acetate (1:1) as mobile phase. 10 % aqueous sodium bicarbonate solution is added (15 mL), stirred and the two layers are separated. The organic layer is washed with water (10 mL), followed by brine solution (10 mL).  The toluene layer containing 1-cyclopropyl-N-(2-nitrobenzyl)methanamine 2 is directly taken to the next step.

Table 2: Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) of 4.

U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.
  x/a y/b z/c U(eq)
O1 0.82588(18) 0.9804(2) 0.92008(15) 0.0479(6)
N1 0.78064(19) 0.0632(3) 0.72761(17) 0.0387(6)
N2 0.9978(2) 0.0651(3) 0.84833(18) 0.0448(6)
C1 0.2253(3) 0.2784(4) 0.7057(3) 0.0526(8)
C2 0.1449(3) 0.2932(4) 0.5908(3) 0.0566(8)
C3 0.0165(3) 0.2300(4) 0.5631(2) 0.0517(8)
C4 0.9672(2) 0.1536(3) 0.6482(2) 0.0392(6)
C5 0.8295(2) 0.0809(4) 0.6211(2) 0.0458(7)
C6 0.6434(2) 0.0108(3) 0.7094(2) 0.0432(7)
C7 0.5339(3) 0.1122(4) 0.6355(2) 0.0521(8)
C8 0.5537(3) 0.1041(4) 0.7666(3) 0.0567(8)
C9 0.1774(3) 0.2023(3) 0.7910(2) 0.0461(7)
C10 0.0481(2) 0.1407(3) 0.7624(2) 0.0372(6)
C11 0.8654(2) 0.0325(3) 0.8358(2) 0.0370(6)

2-{[(cyclopropylmethyl)amino]methyl}aniline (3):The toluene extract with 1-cyclopropyl-N-(2-nitrobenzyl)methanamine 2 is reduced in the presence of 10 % Pd/C (50 % wet) catalyst  in IPA. After 3h stirring at room temperature, the catalyst is filtered off and solvent is removed under vacuum to provide 2-{[(cyclopropylmethyl)amino]methyl}aniline 3 (3.2 g, 0.018 mol) with m.p. 102-104 o C. IR (KBr): νmax 3145, 2951, 1674, 1412; 1H NMR (CDCl3, 400 MHz,): δ= 0.18-0.29 (m, 2H), 0.49-0.53 (m, 2H), 0.91- 1.06 (m, 1H), 2.71 (s, 2H), 3.53 (s, 2H), 4.21 (s, 1H), 7.69-8.76 (m, 4H). EI-MS (110 V) m/z (%):163.24  (M+, 100). Anal. Calcd. for  C10H14N2: C, 74.03; H, 8.70; N, 17.27. Found: C, 74.06; H, 8.77; N, 17.22.

3-cyclopropyl-3,4-dihydroquinazolin-2(1H)-one (4) : N,N’carbonyldiimidazole (2.4 g, 0.01 mol) is added to 2-{[(cyclopropylmethyl)amino]methyl}aniline  (5.3 g, 0.03 mol) in THF (30 mL) at 50 °C. Stirred for 4h and cooled. Two layers are separated and organic layer is given a water wash. Solvent is removed and the mass is stirred with IPA at 40 0C and then cooled to 5 0C. White crystalline solid formed is 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one 4 (3.2 g, 0.01 mol) with m.p. 146-148 o C. IR (KBr): νmax 3109, 2926, 1712, 1665, 1408; 1H NMR (CDCl3, 400 MHz,): δ= 0.15-0.22 (m, 2H), 0.34-0.41 (m, 2H), 0.85- 0.97 (m, 1H), 2.54 (s, 2H), 7.42-8.3 (m, 4H), 10.23 (s, 1H). EI-MS (110 V) m/z (%):189.21 (M+, 100). Anal. Calcd. for C11H12N2O: C, 70.19; H, 6.43; N, 8.50. Found: C, 70.12; H, 6.40; N, 8.55.

Table 3: Bond lengths (Å) of 4. 

O1-C11 1.232(3) N1-C11 1.356(3)
N1-C6 1.439(3) N1-C5 1.459(3)
N2-C11 1.357(3) N2-C10 1.389(3)
N2-H2 0.86 C1-C9 1.370(4)
C1-C2 1.382(4) C1-H1 0.93
C2-C3 1.379(4) C2-H2A 0.93
C3-C4 1.377(3) C3-H3 0.93
C4-C10 1.376(3) C4-C5 1.496(3)
C5-H5A 0.97 C5-H5B 0.97
C6-C8 1.487(4) C6-C7 1.489(4)
C6-H6 0.98 C7-C8 1.486(4)
C7-H7 0.93 C8-H8 0.93
C9-C10 1.382(4) C9-H9 0.93

 

Table 4: Bond angles (°)  of compound 4. 

C11-N1-C6 116.7(2) C11-N1-C5 121.8(2)
C6-N1-C5 116.4(2) C11-N2-C10 124.2(2)
C11-N2-H2 117.9 C10-N2-H2 117.9
C9-C1-C2 120.2(3) C9-C1-H1 119.9
C2-C1-H1 119.9 C3-C2-C1 119.2(3)
C3-C2-H2A 120.4 C1-C2-H2A 120.4
C4-C3-C2 121.0(3) C4-C3-H3 119.5
C2-C3-H3 119.5 C3-C4-C10 119.1(2)
C3-C4-C5 122.6(2) C10-C4-C5 118.3(2)
N1-C5-C4 112.1(2) N1-C5-H5A 109.2
C4-C5-H5A 109.2 N1-C5-H5B 109.2
C4-C5-H5B 109.2 H5A-C5-H5B 107.9
N1-C6-C8 118.2(2) N1-C6-C7 118.6(2)
C8-C6-C7 59.93(19) N1-C6-H6 116.1
C8-C6-H6 116.1 C7-C6-H6 116.1
C8-C7-C6 59.98(18) C8-C7-H7 150.0
C6-C7-H7 150.0 C7-C8-C6 60.10(18)
C7-C8-H8 150.0 C6-C8-H8 150.0
C1-C9-C10 120.0(3) C1-C9-H9 120.0
C10-C9-H9 120.0 C9-C10-C4 120.4(2)
C9-C10-N2 120.6(2) C4-C10-N2 119.0(2)
O1-C11-N1 122.6(2) O1-C11-N2 120.8(2)
N1-C11-N2 116.6(2)

 

X-Ray Data Collection

A specimen of title compound with molecular formula C11H12N2O was used for the X-ray crystallographic analysis. The X-ray intensity data were measured. A total of 1261 frames were collected. The total exposure time was 3.50 hours. The frames were integrated with the Bruker SAINT Software package using a narrow-frame algorithm. Data were corrected for absorption effects using the multi-scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.906. The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P 1 21/n 1, with Z = 4 for the formula unit, C11H12N2O. Crystal data and structure refinement details are tabulated in Table 1. The final positional coordinates of all the atoms, bond distances and bond angles are accounted in Tables 2–4 respectively. Anisotropic atomic displacement and Hydrogen atomic coordinates along with isotropic atomic displacement parameters are depicted in Tables 5 and 6 respectively.

Table 5: Anisotropic atomic displacement parameters (Å2) of compound 4. 

The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + … + 2 h k a* b* U12 ]
  U11 U22 U33 U23 U13 U12
O1 0.0450(11) 0.0623(13) 0.0379(10) 0.0132(9) 0.0133(8) 0.0002(9)
N1 0.0328(11) 0.0488(14) 0.0344(11) 0.0031(9) 0.0083(8) -0.0022(9)
N2 0.0343(11) 0.0633(16) 0.0341(11) 0.0110(10) 0.0040(9) -0.0008(10)
C1 0.0376(14) 0.0585(19) 0.0642(19) 0.0047(14) 0.0175(13) -0.0032(12)
C2 0.0517(17) 0.070(2) 0.0550(18) 0.0089(15) 0.0267(14) -0.0016(15)
C3 0.0438(15) 0.074(2) 0.0397(15) 0.0079(14) 0.0158(12) 0.0018(14)
C4 0.0378(13) 0.0442(15) 0.0371(14) 0.0005(11) 0.0126(10) 0.0040(11)
C5 0.0393(14) 0.0661(19) 0.0319(13) 0.0011(12) 0.0090(10) -0.0053(12)
C6 0.0362(13) 0.0409(15) 0.0527(16) 0.0015(12) 0.0120(11) -0.0056(11)
C7 0.0382(14) 0.073(2) 0.0408(15) 0.0027(14) 0.0021(11) 0.0051(13)
C8 0.0427(15) 0.085(2) 0.0456(16) -0.0006(15) 0.0172(12) 0.0072(14)
C9 0.0351(13) 0.0536(18) 0.0472(15) 0.0013(12) 0.0064(11) 0.0002(12)
C10 0.0361(12) 0.0384(14) 0.0383(14) 0.0033(11) 0.0115(10) 0.0043(10)
C11 0.0380(13) 0.0386(15) 0.0350(13) 0.0033(10) 0.0104(10) 0.0037(10)

 

Table 6: Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) of compound 4. 

x/a y/b z/c U(eq)
H2 1.0541 0.0371 0.9137 0.054
H1 1.3122 0.3202 0.7252 0.063
H2A 1.1771 0.3453 0.5329 0.068
H3 0.9623 0.2390 0.4857 0.062
H5A 0.7675 0.1484 0.5641 0.055
H5B 0.8315 -0.0237 0.5848 0.055
H6 0.6284 -0.1056 0.7040 0.052
H7 0.4873 0.1517 0.5615 0.063
H8 0.5284 0.1349 0.8347 0.068
H9 1.2319 0.1922 0.8681 0.055

 

Results and Discussion

The title compound is synthesized as per scheme 1. 2-nitrobenzylbromide 1 and cyclopropylamine are reacted to afford 1-cyclopropyl-N-(2-nitrobenzyl)methanamine 2, which is reduced to 2-{[(cyclopropylmethyl)amino]methyl}aniline 3. This reduced product is then cyclized to the desired 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one 4 by CDI without getting any undesired side products.

Scheme 1 Scheme 1

Click here to View Scheme

 

Structures of the synthesized compounds are characterized by spectral and elemental analyses. The IR spectrum of 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one 4 shows the characteristic peaks at 3109 for NH stretching and 1712 for C=O stretching. 1H NMR spectrum shows the characteristic signal at δ 10.23 for the NH of quinazolone. LC-MS analysis confirms that the value of the molecular ion peak is in agreement with the calculated formula weight of the title compound.

Figure 1 stands for the ORTEP diagram of the compound 4 at 50% probability with atom numbering. The integration of the data using a monoclinic unit cell yielded a total of 6541 reflections to a maximum θ angle of 25.17° (0.84 Å resolution), of which 1715 were independent (average redundancy 3.814, completeness = 99.8%, Rsig = 3.02%) and 1359 (79.24%) were greater than 2σ(F2). The final cell constants of a = 10.273(2) Å, b = 8.3227(19) Å, c = 11.623(3) Å, β = 104.980(3)°, volume = 960.0(4) Å3, are based upon the refinement of the XYZ-centroids of 2105 reflections above 20 σ(I) with 4.723° < 2θ < 49.16°. The final anisotropic full-matrix least-squares refinement on F2 with 127 variables converged at R1 = 6.50%, for the observed data and wR2 = 20.36% for all data. The goodness-of-fit was 1.486. The largest peak in the final difference electron density synthesis was 0.557 e3 and the largest hole was -0.493 e3 with an RMS deviation of 0.078 e3. On the basis of the final model, the calculated density was 1.288 g/cm3 and F(000), 392 e.

Figure 1: ORTEP diagram of the compound 4 at 50% probability with atom numbering.

Figure 1: ORTEP diagram of the compound 4 at 50% probability with atom numbering.


Click here to View Figure

 

Conclusion

In conclusion, we report the synthesis of 3-cyclopropyl-3, 4-dihydroquinazolin-2(1H)-one 4. CDI is used as efficient reagent for cyclization of amines to quinazolin-2(1H)-one. Work up procedure is easily accessible for lab conditions to get good yield and purity. Modern analytical techniques have characterized the structure of the title compound and single crystal X-ray of the compound is presented.

Acknowledgments

The authors are thankful to Manipal Institute of Technology, Manipal for laboratory facilities and Karnatak University, Dharwad for the XRD.

References

  1. Ugale, V. G.; Bari, S. B.Eur. J. Med. Chem.2014, 80, 447–501.
    CrossRef
  2. Rekha, S. H.; Basavaraj, R. P.; Dayananda, S. B.;Ramesh, S.V.; Kalagouda, B. G.; Prasad, R. D.; Mahesh, M. G.; Subhash, B. P.; Munirathinam, N.Eur. J. Med. Chem.2010,45,2277–2282.
    CrossRef
  3. Yunyun, Z.; Qi, F.; Fegjuan, D.; Qiaoxiao, L.; Duoyi, W.; Youwei, C.; Lixia, X.; Haibin, S.; Yuxin, L.; Zhengming, L.Bioorg. Med. Chem.2013,21, 4968–4975.
    CrossRef
  4. The ivendren, P. S.; Palanirajan, V. K.Res. In.  Pharm.2011, 1, 1-21.
  5. Vijayakumar, B.; Prasanthi, P.; Muni, K. T.; Makesh, K.  K.R.: Nishanthi, P.; Nagendramma, M.; Nishanthi,M. Int. J. Med. Chem. Anal.2013.3, 10-21.
  6. Abida, P. N.;  Rana,  A.; Imran, M. Int. J. Pharma. Bio. Arc.2011,2, 1651-1657.
  7. Wang, H.; Ma, J. Y. J.Chem. Pharma. Res.2012,4,580–582.
  8. Gaonkar, S. L.;Rai, K. M. L.Tet. Lett, 2005, 6,5969-5970.
    CrossRef
  9. Priya, B. S.; Nanjundaswamy, S.; Tejesvi, M. V.; Sarala, G.; Gaonkar, S. L.; Naveen, S.; Shashidhara, P. J.; Rangappa, K. S.Eur. J. Med. Chem,2006,41,1262–1270.
    CrossRef
  10. Gaonkar, S. L.; Rai, K. M. L.; Prabhuswamy, B. Eur. J. Med. Chem. 2006,4, 841-846.
    CrossRef
  11. Gaonkar, S. L.; Shimizu, H. Tetrahedron,2010,66,3314-3317.
    CrossRef
  12. Mahadevaprasad, T. N,;Gaonkar, S. L;Kamini, K.;Vivek, G. K.;Rajnikant;Shimizu, H.;Sridhar, M. A.; Shashidhara, P. J.Anal. Chem. X-ray Analys. Online,2012,28, 25-26.
  13. Namratha, B.; Gaonkar, S. L. Int. Scholarly Res. Notices,2014,  2014, 1-7.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.